Armistice Capital, LLC Crispr Therapeutics Ag Transaction History

Armistice Capital, LLC

$6.02 Billion
Q3 2024

A detailed history of Armistice Capital, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Armistice Capital, LLC holds 200,000 shares of CRSP stock, worth $8.19 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

200,000

Previous 198,357 0.83%

Holding current value

$8.19 Million

Previous $10.7 Million 12.27%

% of portfolio

0.16%

Previous 0.14%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $73,310 - $103,098	1,643 Added 0.83%	200,000 $9.4 Million
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $325,287 - $433,420	6,357 Added 3.31%	198,357 $10.7 Million
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $1.46 Million - $2.14 Million	24,000 Added 14.29%	192,000 $13.1 Million
Q4 2023 Feb 13, 2024	SELL	$38.62 - $72.18 $16.7 Million - $31.2 Million	-432,012 Reduced 72.0%	168,000 $10.5 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $4.54 Million - $5.9 Million	100,012 Added 20.0%	600,012 $27.2 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $14.1 Million - $22 Million	-324,000 Reduced 39.32%	500,000 $28.1 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $8.69 Million - $11.9 Million	-212,000 Reduced 20.46%	824,000 $37.3 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $4.39 Million - $7.36 Million	112,000 Added 12.12%	1,036,000 $42.1 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $4.64 Million - $6.37 Million	-76,000 Reduced 7.6%	924,000 $60.4 Million
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $1.04 Million - $1.77 Million	-24,000 Reduced 2.34%	1,000,000 $60.8 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $7.02 Million - $10.5 Million	132,000 Added 14.8%	1,024,000 $64.3 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $35.9 Million - $57 Million	512,000 Added 134.74%	892,000 $67.6 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $24.5 Million - $34.8 Million	222,000 Added 140.51%	380,000 $42.5 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $201,680 - $323,780	2,000 Added 1.28%	158,000 $25.6 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $9.3 Million - $17.6 Million	84,000 Added 116.67%	156,000 $19 Million
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $10.5 Million - $22.9 Million	-132,000 Reduced 64.71%	72,000 $11 Million
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $1.26 Million - $1.61 Million	16,000 Added 8.51%	204,000 $17.1 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $1.85 Million - $3.65 Million	-48,000 Reduced 20.34%	188,000 $13.8 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $2.96 Million - $5.5 Million	88,000 Added 59.46%	236,000 $10 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $4.25 Million - $8.48 Million	-116,000 Reduced 43.94%	148,000 $9.01 Million
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $10.8 Million - $13.9 Million	264,000 New	264,000 $10.8 Million
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $2.84 Million - $3.86 Million	-80,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$28.02 - $40.87 $2.58 Million - $3.76 Million	-92,000 Reduced 53.49%	80,000 $2.86 Million
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $3.91 Million - $7.28 Million	172,000 New	172,000 $4.91 Million
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $5.5 Million - $8.15 Million	-124,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $5.28 Million - $9.13 Million	124,000 New	124,000 $7.29 Million

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.19B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Crispr Therapeutics Ag Transaction History